Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 05/25/2015
‘The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, today announced the launch of a new fund to assist people living with hepatitis C (also known as HCV). Through the fund, the HealthWell Foundation will provide copayment assistance for HCV treatment, up to $15,000, to eligible patients who are insured and have annual household incomes up to 500 percent of the federal poverty level.’
Hepatitis C virus is moving from chronic disease to curable; however, there are obstacles to eradication and “the hope of ending the hepatitis C epidemic kindled by the new regimens will be extinguished,” Brian R. Edlin, MD, of Weill Medical College of Cornell University, said here. “This is a watershed moment…in the history of medicine,” Edlin said of HCV treatment.
‘Help-4-Hep, a non-profit, peer-to-peer helpline where counselors work with patients to meet the challenges of hepatitis C, is launching today a new web and mobile app to bring its highly effective peer counseling services as well as a new self-care tool to more people affected by hepatitis C.’
‘By treating hepatitis C virus with the latest medications and achieving sustained virologic response, physicians can predict a recoup of nearly $3 billion of the estimated $7 billion financial loss seen in the United States, according to an expert here at DDW 2015.’
‘NASH, or nonalcoholic steatohepatitis, is often billed as the “silent liver disease,” since many people with it feel well. But NASH, which is estimated to affect 2-3% of the U.S. population, can eventually lead to liver scarring, liver failure, and death.’
A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new antiviral drugs. Rallying baby boomers to be screened for hepatitis C took off as effective treatments emerged to wipe out the liver-damaging virus.’